JP2000515368A5 - - Google Patents

Download PDF

Info

Publication number
JP2000515368A5
JP2000515368A5 JP1998505190A JP50519098A JP2000515368A5 JP 2000515368 A5 JP2000515368 A5 JP 2000515368A5 JP 1998505190 A JP1998505190 A JP 1998505190A JP 50519098 A JP50519098 A JP 50519098A JP 2000515368 A5 JP2000515368 A5 JP 2000515368A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998505190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000515368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/009690 external-priority patent/WO1998001564A1/en
Publication of JP2000515368A publication Critical patent/JP2000515368A/ja
Publication of JP2000515368A5 publication Critical patent/JP2000515368A5/ja
Ceased legal-status Critical Current

Links

JP10505190A 1996-07-08 1997-07-03 Hivエンベロープポリペプチドおよびワクチン Ceased JP2000515368A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08
US08/676,737 1996-07-08
PCT/US1997/009690 WO1998001564A1 (en) 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine

Publications (2)

Publication Number Publication Date
JP2000515368A JP2000515368A (ja) 2000-11-21
JP2000515368A5 true JP2000515368A5 (enExample) 2005-03-10

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10505190A Ceased JP2000515368A (ja) 1996-07-08 1997-07-03 Hivエンベロープポリペプチドおよびワクチン

Country Status (13)

Country Link
US (1) US6090392A (enExample)
EP (1) EP0942988A1 (enExample)
JP (1) JP2000515368A (enExample)
AP (1) AP1282A (enExample)
AU (1) AU727107B2 (enExample)
CA (1) CA2259965A1 (enExample)
ID (1) ID17767A (enExample)
IL (2) IL127701A0 (enExample)
NZ (1) NZ333500A (enExample)
OA (1) OA10954A (enExample)
TW (1) TWI221846B (enExample)
WO (1) WO1998001564A1 (enExample)
ZA (1) ZA975889B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046392A1 (en) * 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
CA2398816A1 (en) 2000-02-04 2001-08-09 Duke University Human immunodeficiency virus vaccine
WO2001083535A2 (en) * 2000-05-02 2001-11-08 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AU2001291049A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
US7897152B2 (en) 2000-09-18 2011-03-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-antigen fusion proteins
US20060116325A1 (en) * 2001-02-15 2006-06-01 Oleg Chertov Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
CA2505583C (en) * 2002-12-03 2014-07-15 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
AU2004247146A1 (en) * 2003-06-12 2004-12-23 Vaxgen, Inc. HIV-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
WO2005040816A1 (en) 2003-10-24 2005-05-06 Immunaid Pty Ltd Method of therapy
JP5386083B2 (ja) * 2004-09-08 2014-01-15 イミューンネイド ピーティーワイ リミテッド 自己免疫疾患および変性疾患を治療する方法
AU2005284922B2 (en) * 2004-09-14 2010-12-23 Coimmune, Inc. Strain independent amplification of pathogens and vaccines thereto
CN101313216A (zh) * 2005-09-22 2008-11-26 普洛茨股份有限公司 酵母突变体中产生的糖基化多肽及其使用方法
WO2009017743A2 (en) 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides
BRPI0914224A2 (pt) 2008-06-19 2019-09-24 Variation Biotechnologies Inc composições e métodos para tratar a gripe
US9122778B2 (en) 2009-05-27 2015-09-01 Biotempus Limited Methods of treating diseases
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US9951106B2 (en) 2012-12-04 2018-04-24 University Of Maryland, Baltimore Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187041B1 (en) * 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
ES2102347T3 (es) * 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
CA2066607A1 (en) * 1989-09-22 1991-03-23 Thomas Kieber-Emmons Peptides associated with the cd4 binding region of gp120 and their methods of use
JPH05506221A (ja) * 1990-04-03 1993-09-16 ジェネンテク,インコーポレイテッド Hivエンベロープポリペプチド
DK0527760T3 (da) * 1990-04-03 1995-11-27 Genentech Inc Fremgangsmåder og præparater til vaccination mod HIV
CA2164505A1 (en) * 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides

Similar Documents

Publication Publication Date Title
JP2001502189A5 (enExample)
JP2001500031A5 (enExample)
JP2001508893A5 (enExample)
JP2002511982A5 (enExample)
JP2001507965A5 (enExample)
JP2001505080A5 (enExample)
JP2002510439A5 (enExample)
JP2001505071A5 (enExample)
JP2000511700A5 (enExample)
JP2000515576A5 (enExample)
JP2001501409A5 (enExample)
JP2002514905A5 (enExample)
JP2001508089A5 (enExample)
JP2001503031A5 (enExample)
JP2000509399A5 (enExample)
JP2001501933A5 (enExample)
JP2001506386A5 (enExample)
JP2001504146A5 (enExample)
JP2001503521A5 (enExample)
JP2000517299A5 (enExample)
JP2001502569A5 (enExample)
JP2001506363A5 (enExample)
JP2000515368A5 (enExample)
JP2001500723A5 (enExample)
JP2002513392A5 (enExample)